{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:13:26Z","timestamp":1794255206710,"version":"4.9.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1038\/s41409-025-02595-1","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T11:31:30Z","timestamp":1745321490000},"page":"1065-1069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT)"],"prefix":"10.1038","volume":"60","author":[{"given":"Piyatida","family":"Chumnumsiriwath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pongthep","family":"Vittayawacharin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Ramos-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jeyakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1678-1345","authenticated-orcid":false,"given":"Benjamin J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Doh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-2490","authenticated-orcid":false,"given":"Shawn","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramy M.","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh-Ha","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piyanuch","family":"Kongtim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8597-3271","authenticated-orcid":false,"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"2595_CR1","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","volume":"56","author":"JA Young","year":"2021","unstructured":"Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transpl. 2021;56:1805\u201317. https:\/\/doi.org\/10.1038\/s41409-021-01283-0.","journal-title":"Bone Marrow Transpl"},{"key":"2595_CR2","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood.2023022526","volume":"143","author":"S Jodele","year":"2024","unstructured":"Jodele S, Dandoy CE, Aguayo-Hiraldo P, Lane A, Teusink-Cross A, Sabulski A, et al. A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA. Blood. 2024;143:1112\u201323. https:\/\/doi.org\/10.1182\/blood.2023022526.","journal-title":"Blood"},{"key":"2595_CR3","doi-asserted-by":"publisher","unstructured":"Ben\u00edtez Carabante MI, Bueno D, Alonso Garc\u00eda L, L\u00f3pez Torija I, Marsal J, Fernandez Navarro JM, et al. Use of eculizumab in pediatric patients with high-risk transplantation-associated thrombotic microangiopathy: outcomes and risk factors associated with response and survival. a retrospective study on behalf of the spanish group for hematopoietic transplantation and cellular therapy (GETH-TC). Transpl Cell Ther. 2024;30:601.e601.e613. https:\/\/doi.org\/10.1016\/j.jtct.2024.03.019.","DOI":"10.1016\/j.jtct.2024.03.019"},{"key":"2595_CR4","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1200\/jco.21.02389","volume":"40","author":"SK Khaled","year":"2022","unstructured":"Khaled SK, Claes K, Goh YT, Kwong YL, Leung N, Mendrek W, et al. Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation-associated thrombotic microangiopathy. J Clin Oncol. 2022;40:2447\u201357. https:\/\/doi.org\/10.1200\/jco.21.02389.","journal-title":"J Clin Oncol"},{"key":"2595_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jtct.2022.11.015","volume":"29","author":"ML Schoettler","year":"2023","unstructured":"Schoettler ML, Carreras E, Cho B, Dandoy CE, Ho VT, Jodele S, et al. Harmonizing definitions for diagnostic criteria and prognostic assessment of transplantation-associated thrombotic microangiopathy: a report on behalf of the european society for blood and marrow transplantation, american society for transplantation and cellular therapy, asia-pacific blood and marrow transplantation group, and center for international blood and marrow transplant research. Transpl Cell Ther. 2023;29:151\u201363. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.015.","journal-title":"Transpl Cell Ther"},{"key":"2595_CR6","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41409-024-02305-3","volume":"59","author":"M Castelli","year":"2024","unstructured":"Castelli M, Mic\u00f2 MC, Grassi A, Algarotti A, Lussana F, Finazzi MC, et al. Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience. Bone Marrow Transpl. 2024;59:1161\u20138. https:\/\/doi.org\/10.1038\/s41409-024-02305-3.","journal-title":"Bone Marrow Transpl"},{"key":"2595_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/bloodadvances.2020003455","volume":"5","author":"CE Dandoy","year":"2021","unstructured":"Dandoy CE, Rotz S, Alonso PB, Klunk A, Desmond C, Huber J, et al. A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. Blood Adv. 2021;5:1\u201311. https:\/\/doi.org\/10.1182\/bloodadvances.2020003455.","journal-title":"Blood Adv"},{"key":"2595_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.bbmt.2004.03.002","volume":"10","author":"A Shimoni","year":"2004","unstructured":"Shimoni A, Yeshurun M, Hardan I, Avigdor A, Ben-Bassat I, Nagler A. Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced. Biol Blood Marrow Transpl. 2004;10:484\u201393. https:\/\/doi.org\/10.1016\/j.bbmt.2004.03.002.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2595_CR9","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood.2019004218","volume":"135","author":"S Jodele","year":"2020","unstructured":"Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020;135:1049\u201357. https:\/\/doi.org\/10.1182\/blood.2019004218.","journal-title":"Blood"},{"key":"2595_CR10","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1182\/bloodadvances.2021006523","volume":"6","author":"K Mizuno","year":"2022","unstructured":"Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S. Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv. 2022;6:1454\u201363. https:\/\/doi.org\/10.1182\/bloodadvances.2021006523.","journal-title":"Blood Adv"},{"key":"2595_CR11","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1016\/j.jtct.2024.01.031","volume":"30","author":"Y Samara","year":"2024","unstructured":"Samara Y, Yao J, Tsai N-C, Mokhtari S, Aldoss I, Ali H, et al. Eculizumab treatment outcomes in patients with allogeneic hematopoietic cell transplant (alloHCT)-associated thrombotic microangiopathy (TA-TMA): a retrospective single-center experience. Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther. 2024;30:S136\u20137. https:\/\/doi.org\/10.1016\/j.jtct.2024.01.031","journal-title":"Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther"},{"key":"2595_CR12","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s00277-017-3092-9","volume":"96","author":"J Qi","year":"2017","unstructured":"Qi J, Wang J, Chen J, Su J, Tang Y, Wu X, et al. Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation. Ann Hematol. 2017;96:1849\u201355. https:\/\/doi.org\/10.1007\/s00277-017-3092-9.","journal-title":"Ann Hematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02595-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02595-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T03:06:01Z","timestamp":1751857561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-025-02595-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":12,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["2595"],"URL":"https:\/\/doi.org\/10.1038\/s41409-025-02595-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients provided written informed consent for transplant, and consent for research data collection\/report, in accordance with the Declaration of Helsinki [UCI International Review Board (IRB #20206215)]. Patients who received narsoplimab were treated on a compassionate basis and signed a single IND protocol approved by UCI Institutional Review Board. The STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for cohort studies were followed. All methods were performed in accordance with guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}